Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis
Status:
Terminated
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety and efficacy of Besivance (besifloxacin
0.6%) ophthalmic suspension compared to gatifloxacin 0.3% ophthalmic solution when
administered three times daily (TID) for seven days to neonatal subjects who are 31 days or
younger on the day of randomization (Visit 1).